导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.84% | 3556/4773 |
| 近一周 | -4.86% | 5136/5462 |
| 近一月 | -4.29% | 2360/5421 |
| 近一季 | -11.93% | 3783/5209 |
| 近半年 | -16.98% | 4144/4920 |
| 近一年 | 15.48% | 672/4366 |
| 近两年 | 102.49% | 588/2954 |
| 近三年 | 71.40% | 296/2253 |
| 成立以来 | 110.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.63% 1229/4961 |
-6.28% 3685/5312 |
- - |
- - |
| 2025 | 92.57% 40/4813 |
10.24% 325/3635 |
5.09% 651/4076 |
43.63% 647/4524 |
15.72% 52/4813 |
| 2024 | 3.35% 1931/3463 |
9.96% 95/2808 |
-5.34% 1697/3014 |
11.54% 2505/3129 |
-10.97% 3010/3463 |
| 2023 | -10.98% 1357/2656 |
5.32% 800/2280 |
-7.88% 1927/2385 |
-4.19% 1084/2515 |
-4.23% 923/2655 |
| 2022 | -20.06% 927/2207 |
-7.46% 247/1919 |
5.66% 848/2016 |
-16.36% 1447/2113 |
-2.25% 1790/2208 |
| 2021 | 32.34% 56/1822 |
0.11% 314/1255 |
10.85% 429/1330 |
21.56% 42/1466 |
-1.89% 1396/1822 |
| 2020 | 36.11% 403/1250 |
-12.64% 894/1028 |
11.43% 731/1067 |
7.36% 789/1164 |
30.24% 20/1184 |
| 2019 | 26.83% 561/1092 |
19.93% 617/739 |
-2.64% 353/788 |
-3.28% 735/850 |
12.30% 40/918 |
| 2018 | -37.99% 604/834 |
- - |
-15.92% 541/631 |
-10.95% 554/660 |
-13.23% 520/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证申万有色金属ETF发起联接C VS. 长安沪深300非周期A(740101) |